These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 15101566)

  • 1. Sulpiride augmentation of olanzapine in the management of treatment-resistant chronic schizophrenia: evidence for improvement of mood symptomatology.
    Kotler M; Strous RD; Reznik I; Shwartz S; Weizman A; Spivak B
    Int Clin Psychopharmacol; 2004 Jan; 19(1):23-6. PubMed ID: 15101566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.
    Lecrubier Y; Quintin P; Bouhassira M; Perrin E; Lancrenon S
    Acta Psychiatr Scand; 2006 Nov; 114(5):319-27. PubMed ID: 17022791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Olanzapine and sulpiride: a preliminary study of combination/augmentation in patients with treatment-resistant schizophrenia.
    Raskin S; Durst R; Katz G; Zislin J
    J Clin Psychopharmacol; 2000 Oct; 20(5):500-3. PubMed ID: 11001233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression.
    Vanelle JM; Douki S
    Eur Psychiatry; 2006 Dec; 21(8):523-30. PubMed ID: 17113759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Augmentation treatment with amisulpride in schizophrenic patients partially responsive to olanzapine.
    Molina JD; Toledo-Romero F; López-Rodríguez E; Amorin-Díaz M; Lerma-Carrillo I; López-Muñoz F
    Pharmacopsychiatry; 2011 Jun; 44(4):142-7. PubMed ID: 21710404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial.
    Strous RD; Stryjer R; Maayan R; Gal G; Viglin D; Katz E; Eisner D; Weizman A
    Psychoneuroendocrinology; 2007 Feb; 32(2):96-105. PubMed ID: 17208382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia.
    Mortimer A; Martin S; Lôo H; Peuskens J;
    Int Clin Psychopharmacol; 2004 Mar; 19(2):63-9. PubMed ID: 15076013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia.
    Meltzer HY; Bobo WV; Roy A; Jayathilake K; Chen Y; Ertugrul A; Anil Yağcioğlu AE; Small JG
    J Clin Psychiatry; 2008 Feb; 69(2):274-85. PubMed ID: 18232726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.
    Tollefson GD; Sanger TM; Lu Y; Thieme ME
    Arch Gen Psychiatry; 1998 Mar; 55(3):250-8. PubMed ID: 9510219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial.
    Lindenmayer JP; Volavka J; Lieberman J; Sheitman B; Citrome L; Chakos M; Czobor P; Parker B; Iskander A
    J Clin Psychopharmacol; 2001 Aug; 21(4):448-53. PubMed ID: 11476131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial.
    Bhowmick S; Hazra A; Ghosh M
    Aust N Z J Psychiatry; 2010 Mar; 44(3):237-42. PubMed ID: 20050717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
    Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
    Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
    Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
    J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes in schizophrenia outpatients treated with amisulpride or olanzapine.
    Hofer A; Rettenbacher MA; Edlinger M; Huber R; Bodner T; Kemmler G; Sachs G; Fleischhacker WW
    Pharmacopsychiatry; 2007 Jan; 40(1):1-8. PubMed ID: 17327953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
    Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP
    J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
    Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
    J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.
    Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M
    J Clin Psychiatry; 2004 Apr; 65(4):551-6. PubMed ID: 15119920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olanzapine therapy in treatment-resistant psychotic mood disorders: a long-term follow-up study.
    Narendran R; Young CM; Valenti AM; Pristach CA; Pato MT; Grace JJ
    J Clin Psychiatry; 2001 Jul; 62(7):509-16. PubMed ID: 11488360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmentation of olanzapine in treatment-resistant schizophrenia.
    Zink M
    J Psychiatry Neurosci; 2005 Nov; 30(6):409-15. PubMed ID: 16327874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.